Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3146-3158

  Patwardhan, Parag P ^a   Surriga, Oliver ^a   Beckman, Michael J ^a   De Stanchina, Elisa ^a   Dematteo, Ronald P ^a   Tap, William D ^a   Schwartz, Gary K ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLX 3397; PROTEIN P53; PROTEIN TYROSINE KINASE; RAPAMYCIN; RETINOBLASTOMA PROTEIN; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; 5-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL)-N-((6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE AMPLIFICATION; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C KIT; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG SCREENING; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NEURILEMMOMA; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL PROLIFERATION; HUMANS; IMATINIB MESYLATE; MACROPHAGES; MICE; MICE, INBRED ICR; MICE, SCID; NEURILEMMOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIROLIMUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902689895     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2576     Document Type: Article

References (47)

1. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofi bromatosis. Cancer Res 2002;62:1573-7. (Pubitemid 34407825)
2. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 2007;15:131-8. (Pubitemid 46111848)
3. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13:2-7. (Pubitemid 43963395)
4. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-4. (Pubitemid 34526349)
5. McCaughan JA, Holloway SM, Davidson R, Lam WW. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofi bromatosis type 1. J Med Genet 2007;44:463-6. (Pubitemid 47056874)
6. Martin Liberal J, Lagares-Tena L, Sainz-Jaspeado M, Mateo-Lozano S, Garcia Del Muro X, Tirado OM. Targeted therapies in sarcomas: challenging the challenge. Sarcoma 2012;2012:626094.
7. Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008;15:47-54. (Pubitemid 351481991)
8. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, et al. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 2010;98:11-9.
9. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2006;27:664-71. (Pubitemid 43372895)
10. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, et al. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest 2007;87:767-79. (Pubitemid 47077256)
11. Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. PLoS ONE 2010;5:e11858.
12. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865-78.
13. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91-102. (Pubitemid 44692417)
14. Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, et al. Imatinib mesylate for plexiform neurofi bromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 13:1218-24.
15. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008;14:4550-5.
16. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
17. Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 2013;125:159-68.
18. Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2008;7:890-6. (Pubitemid 351551042)
19. Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O'Connor R, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006;66:5858-66. (Pubitemid 43927140)
20. Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 17:3943-55.
21. Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M, et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res 17:7563-73.
22. Cavnar MJ, Zeng S, Kim TS, Sorenson EC, Ocuin LM, Balachandran VP, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med 2013;210:2873-86.
23. Dewar AL, Zannettino AC, Hughes TP, Lyons AB. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle 2005;4:851-3. (Pubitemid 41359742)
24. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor cfms is a novel target of imatinib. Blood 2005;105:3127-32.
25. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012;441:1-21.
26. Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2011;22:280-7.
27. Agulnik M. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer 2012;118:1486-97.
28. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
29. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007;13:7280-7.
30. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 2009;69:6565-72.
31. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008;14:5124-30.
32. Imai Y, Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 2002;40:164-74. (Pubitemid 35337374)
33. Sweet MJ, Hume DA. CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp 2003;51:169-77. (Pubitemid 36828179)
34. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, SymonsMH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 18:519-27.
35. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, et al. Rapamycin unbalances the polarization ofhuman macrophages to M1. Immunology 2013;140:179-90.
36. Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA. The role of neurofi bromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem 2010;344:267-76.
37. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009;11:725-36.
38. Torres KE, Liu J, Young E, Huang KL, Ghadimi M, Lusby K, et al. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology 2011;59:156-9.
39. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-8. (Pubitemid 46548969)
40. Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 2008;10:946-57.
41. Hatzimichael E, Georgiou G, Benetatos L, Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res 3:29-51.
42. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008;18:56-62.
43. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005;102:8573-8. (Pubitemid 40862777)
44. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012;2012:948098.
45. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G, Inoue M. Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 2003;23:4395-409. (Pubitemid 37474893)
46. Tang X,Mo C, Wang Y, Wei D, Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013;138:93-104.
47. Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res 2012;72:1363-72.